Why Did Two Americans Get a Potential Ebola Cure As Africans Die?

Your News Companion by Ben Mathis-Lilley
Aug. 6 2014 3:27 PM

Why Did Two Americans Get a Potential Ebola Cure As Hundreds of Africans Die?

The two American missionaries diagnosed with Ebola virus are receiving treatment at Emory University Hospital.

Photo by Jessica McGowan/Getty Images

While the death toll of the Ebola outbreak has risen to 932, two white American health workers have been treated with an experimental serum called ZMapp—which had previously only been tested on monkeys. Why have they received this potential cure as hundreds of Africans die?

It boils down to logistics and precedent, writes Arthur Caplan, director of the medical ethics division head at NYU Langone Medical Center. Today in the Washington Post, Caplan explains how pharmaceutical companies think about untested drugs and how rural West Africa’s poverty denied it access to the experimental treatment. For one, drugs like ZMapp that contain monoclonal antibodies tend to cost “tens of thousands of dollars,” which institutions in the afflicted countries may not be able to afford. They also lack the infrastructure to handle the serum—ZMapp "requires a lot of refrigeration and careful handling, plus close monitoring by experienced doctors and scientists." The Americans, meanwhile, constitute "a small group" in "a carefully controlled setting" that allows the drug's creator, Mapp Pharmaceuticals, to watch closely for any unforeseen adverse consequences.


Moreover, Caplan writes: the Americans—by way of their missionary group, Samaritan's Purse, and the Centers for Disease Control and National Institute of Health—asked Mapp for the drug, and the West Africans apparently didn't. There is simply no existing framework, he says, by which institutions in outbreak countries can contact and negotiate with pharmaceutical providers. His piece ends with a call for the establishment for policies that would facilitate such potentially life-saving communication.

The two Americans are currently receiving treatment at Emory University hospital in Atlanta and appear to be showing signs of recovery. Read Caplan's entire piece here.

Irene Chidinma Nwoye is a writer and former Slate intern in New York City. Follow her on Twitter.



More Than Scottish Pride

Scotland’s referendum isn’t about nationalism. It’s about a system that failed, and a new generation looking to take a chance on itself. 

What Charles Barkley Gets Wrong About Corporal Punishment and Black Culture

Why Greenland’s “Dark Snow” Should Worry You

Three Talented Actresses in Three Terrible New Shows

Why Do Some People See the Virgin Mary in Grilled Cheese?

The science that explains the human need to find meaning in coincidences.


Happy Constitution Day!

Too bad it’s almost certainly unconstitutional.

Is It Worth Paying Full Price for the iPhone 6 to Keep Your Unlimited Data Plan? We Crunch the Numbers.

What to Do if You Literally Get a Bug in Your Ear

  News & Politics
Sept. 17 2014 8:15 AM Ted Cruz Will Not Join a Protest of "The Death of Klinghoffer" After All
Sept. 16 2014 2:35 PM Germany’s Nationwide Ban on Uber Lasted All of Two Weeks
The Vault
Sept. 16 2014 12:15 PM “Human Life Is Frightfully Cheap”: A 1900 Petition to Make Lynching a Federal Offense
  Double X
The XX Factor
Sept. 15 2014 3:31 PM My Year As an Abortion Doula
  Slate Plus
Slate Plus Video
Sept. 16 2014 2:06 PM A Farewell From Emily Bazelon The former senior editor talks about her very first Slate pitch and says goodbye to the magazine.
Brow Beat
Sept. 17 2014 9:03 AM My Father Was James Brown. I Watched Him Beat My Mother. And Then I Found Myself With Someone Like Dad.
Future Tense
Sept. 17 2014 8:27 AM Only Science Fiction Can Save Us! What sci-fi gets wrong about income inequality.
  Health & Science
Bad Astronomy
Sept. 17 2014 7:30 AM Ring Around the Rainbow
Sports Nut
Sept. 15 2014 8:41 PM You’re Cut, Adrian Peterson Why fantasy football owners should release the Minnesota Vikings star.